Research Topics
| S R MarderSummaryAffiliation: University of California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Overview of partial complianceStephen R Marder
VA Greater Los Angeles Health Care System, West Los Angeles Health Center, and the Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, 90073, USA
J Clin Psychiatry 64:3-9. 2003..Strategies for managing partial compliance include the treatment of medication side effects, the education of patients about their illness, and the use of long-acting antipsychotic formulations...- Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled studyStephen R Marder
Veteran s Affairs Veteran s Integrated Service Networks 22 Mental Illness Research, Education, and Clinical Center, Los Angeles, California 90073, USA
Biol Psychiatry 62:1363-70. 2007..Paliperidone extended-release tablet (paliperidone ER; Invega, Janssen L.P., Titusville, New Jersey) is an oral psychotropic for schizophrenia treatment... 
Selective corticostriatal dysfunction in schizophrenia: examination of motor and cognitive skill learningKarin Foerde
Department of Psychology, University of California Los Angeles, Los Angeles, CA, USA
Neuropsychology 22:100-9. 2008..In contrast, patients were not impaired at learning on the SRT relative to controls, suggesting that patients with schizophrenia may have dysfunction in a specific corticostriatal subcircuit...- Drug initiatives to improve cognitive functionStephen R Marder
Semel Institute of Neuroscience and Human Behavior at UCLA and the Mental Illness Research, Education, and Clinical Center MIRECC, West Los Angeles VA Healthcare Center, Los Angeles, CA 90073, USA
J Clin Psychiatry 67:31-5; discussion 36-42. 2006.... - The Mount Sinai conference on the pharmacotherapy of schizophreniaStephen R Marder
VA Desert Pacific Mental Illness Research Education and Clinical Center, West Los Angeles VA Health Care Center, CA 90073, USA
Schizophr Bull 28:5-16. 2002.... - Can clinical practice guide a research agenda?Stephen R Marder
VA Desert Pacific Mental Illness Research Education and Clinical Center, West Los Angeles VA Health Care Center, CA 90073, USA
Schizophr Bull 28:127-9. 2002..This commentary suggests that these practices can be used to define important research questions... - Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophreniaStephen R Marder
UCLA Neuropsychiatric Institute and the VISN 22 Mental Illness Research, Education, and Clinical Center, MIRECC 210A, West Los Angeles VA Healthcare Center, Los Angeles, CA 90073, USA
Schizophr Res 72:5-9. 2004..S. Food and Drug Administration (FDA) to clarify guidelines for the design of clinical trials for cognition enhancing agents; and finally, to assist NIMH in developing its research agenda in this area... - Physical health monitoring of patients with schizophreniaStephen R Marder
Department of Veterans Affairs Greater Los Angeles Healthcare System, CA, USA
Am J Psychiatry 161:1334-49. 2004..The authors discuss a consensus panel's recommendations for improving the physical health monitoring of patients with schizophrenia who are treated in outpatient settings... - Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoateS R Marder
VA Greater Los Angeles Health Care System, West Los Angeles Health Center and the Department of Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA 90073, USA
Schizophr Res 53:25-30. 2002..With this in mind, we evaluated the usefulness of monitoring fluphenazine plasma levels for patients with schizophrenia who were receiving maintenance treatment with fluphenazine decanoate... - Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trialsStephen R Marder
Semel Institute of Neuroscience, UCLA, Los Angeles, Calif, USA
J Clin Psychiatry 68:662-8. 2007..In order to determine whether baseline agitation level influences treatment response, the effects of oral aripiprazole in acute patients with schizophrenia experiencing either higher or lower levels of agitation were examined... - Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitationStephen R Marder
Building 210, Room 130, West Los Angeles VA Healthcare Center, 11301 Wilshire Blvd, Los Angeles, CA 90073, USA
J Clin Psychiatry 71:433-41. 2010..Safety data from the first 21 months of olanzapine IM, approved in the United States for the treatment of agitation associated with schizophrenia and bipolar disorder, are presented... - Two-year outcome of social skills training and group psychotherapy for outpatients with schizophreniaS R Marder
West Los Angeles VA Medical Center, CA 90073, USA
Am J Psychiatry 153:1585-92. 1996.... - Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trialsStephen R Marder
Department of Psychiatry, David Geffen School of Medicine at UCLA, 760 Westwood Plaza, 90024, Los Angeles, CA, USA
Schizophr Res 61:123-36. 2003..Aripiprazole's safety profile may offer benefits in schizophrenia treatment... 
The NIMH-MATRICS project for developing cognition-enhancing agents for schizophreniaStephen R Marder
Semel Institute of Neuroscience, University of California at Los Angeles, Calif, USA
Dialogues Clin Neurosci 8:109-13. 2006....- Antipsychotic drugs and relapse preventionS R Marder
Psychiatry Service, West Los Angeles Veterans Affairs Medical Center, CA 90073, USA
Schizophr Res 35:S87-92. 1999..Other potential advantages of the newer drugs over the older drugs include the likelihood that they are more effective against negative and cognitive symptoms of schizophrenia... - Novel antipsychotics: comparison of weight gain liabilitiesD A Wirshing
Department of Psychiatry, V A Greater Los Angeles Healthcare System, CA 90073, USA
J Clin Psychiatry 60:358-63. 1999..We hypothesized that the unique pharmacodynamic profiles of these agents would contribute to different amounts and patterns of weight gain... - The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studiesPhilip G Janicak
Department of Psychiatry, Rush University Medical Center, Chicago, Illinoise 60612, USA
J Clin Psychiatry 70:25-35. 2009..To evaluate the efficacy of aripiprazole across a range of symptoms-positive, negative, disorganized thought, depression/anxiety, and hostility-in schizophrenia and schizoaffective disorder... - A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapyJohn M Kane
Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004 1150, USA
J Clin Psychiatry 70:1348-57. 2009..Combining antipsychotics is common practice in the treatment of schizophrenia. This study investigated aripiprazole adjunctive to risperidone or quetiapine for treating schizophrenia and schizoaffective disorder... - Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparisonJ M Kane
Department of Psychiatry, Hillside Hospital, Glen Oaks, NY 11004, USA
Arch Gen Psychiatry 58:965-72. 2001..Advantages are seen in a broad range of symptoms but do not extend to negative symptoms... - Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomesStephen R Marder
Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90073, USA
Am J Psychiatry 160:1405-12. 2003..However, risperidone-treated patients appeared to feel subjectively better, as indicated by less anxiety and depression and fewer extrapyramidal side effects... - The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 updateAlexander L Miller
Department of Psychiatry, The University of Texas Health Science Center at San Antonio, MC 7792, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
J Clin Psychiatry 65:500-8. 2004..This article reports the recommendations developed in 2002 and 2003 by a group of experts, clinicians, and administrators... - Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorderSteven G Potkin
Brain Imaging Center, University of California, Irvine, 92697, USA
Arch Gen Psychiatry 60:681-90. 2003..This multicenter trial examined the efficacy, safety, and tolerability of aripiprazole in patients with acute exacerbation of schizophrenia or schizoaffective disorder... - The effects of clozapine and risperidone on spatial working memory in schizophreniaSusan R McGurk
Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L Levy Pl, New York, NY 10029, USA
Am J Psychiatry 162:1013-6. 2005..The purpose of this investigation was to evaluate the effects of clozapine and risperidone on spatial working memory in patients with schizophrenia... - Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/electrospray tandem mass spectrometryM Aravagiri
Psychopharmacology Unit, University of California at Los Angeles, VA Greater Los Angeles Healthcare System, 11301 Wilshire Boulevard, Los Angeles, California 90073, USA
J Mass Spectrom 35:718-24. 2000..This method is being used for the therapeutic drug monitoring of schizophrenic patients treated with RSP and to study the pharmacokinetics and tissue distribution of RSP and 9-OH-RSP in rats... - Neuroleptic plasma levelsT Van Putten
Veterans Affairs Medical Center, Los Angeles, CA 90073
Schizophr Bull 17:197-216. 1991..Antipsychotic plasma levels may be most useful when the distinction between side effects and worsening psychosis is unclear. The utility of high neuroleptic plasma levels in the treatment-resistant patient is unclear... - Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of ratM Aravagiri
Psychopharmacology Unit, University of California at Los Angeles, West Los Angeles VAMC, 90073, USA
Psychopharmacology (Berl) 139:356-63. 1998..04). The low brain/plasma ratio of high potency RSP and 9-OH-RSP may in part be due to their low lipophilicity, log P = 3.04 and 2.32, respectively, resulting in limited non-specific accumulation in brain tissue... - Prefrontal-posterior parietal networks in schizophrenia: primary dysfunctions and secondary compensationsJavier Quintana
West Los Angeles Department of Veterans Affairs Health Care Center and Department of Psychiatry, University of California at Los Angeles, School of Medicine, USA
Biol Psychiatry 53:12-24. 2003..CONCLUSIONS: In schizophrenia, a PFC dysfunction results in hypo- or hyperfrontality as a function of whether other alternate areas of a PFC-PPC network for WM are available and efficacious in supporting specific task demands... - Clinical guidelines: Dosing and switching strategies for long-acting risperidoneStephen R Marder
VA Greater Los Angeles Health Care System, West Los Angeles Health Center, and the Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, USA
J Clin Psychiatry 64:41-6. 2003 - The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidoneMichael F Green
Veterans Affairs VISN 22 Mental Illness Research Education and Clinical Center, Los Angeles, California, USA
Biol Psychiatry 51:972-8. 2002..We speculate that conventional medications may have neurocognitive benefits at low doses that are neutralized or reversed at higher doses... - Simultaneous determination of clozapine and its N-desmethyl and N-oxide metabolites in plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patientsM Aravagiri
Psychopharmacology Unit, Room 4 B151H Building 210, VA Greater Los Angeles Healthcare System, 11301 Wilshire Blvd, Los Angeles, CA 90073, USA
J Pharm Biomed Anal 26:301-11. 2001..The data revealed that the norclozapine and clozapine N-oxide metabolites were present at about 58%+/-14% and 17%+/-6% of clozapine concentrations in plasma, respectively... - Remission in schizophrenia: proposed criteria and rationale for consensusNancy C Andreasen
Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA
Am J Psychiatry 162:441-9. 2005..These criteria should facilitate research and support a positive, longer-term approach to studying outcome in patients with schizophrenia... - The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 updateTroy A Moore
Department of Psychiatry, The University of Texas Health Science Center at San Antonio, USA
J Clin Psychiatry 68:1751-62. 2007.... - Treatment of agitation in patients with schizophreniaStephen R Marder
Department of Psychiatry and Biobehavioral Sciences, Mental Illness Research, Education, and Clinical Center, West Los Angeles VA Healthcare Center, Los Angeles, Calif, USA
J Clin Psychiatry 69:e17. 2008..Treatment selection for the agitated patient with schizophrenia involves weighing factors including, but not limited to, the medication's efficacy, side effects, and formulation, as well as the patient's medical history... - Pharmacokinetics and tissue distribution of olanzapine in ratsM Aravagiri
Psychopharmacology Unit, University of California at Los Angeles, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA
Biopharm Drug Dispos 20:369-77. 1999..p. administration. The plasma concentration appears to predict the simultaneous concentration in brain and other tissues. There was no marked localized accumulation of olanzapine in any of the regions of the rat brain... - Does risperidone improve verbal working memory in treatment-resistant schizophrenia?M F Green
UCLA Department of Psychiatry and Biobehavioral Sciences 90024 1759, USA
Am J Psychiatry 154:799-804. 1997.... - Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization StudyMichael F Green
Semel Institute for Neuroscience and Human Behavior, UCLA, 300 Medical Plaza, Rm 2263, Los Angeles, CA 90095 6968, USA
Am J Psychiatry 165:221-8. 2008..e., a co-primary) that is considered functionally meaningful. The goal of the current study was to describe steps to evaluate four potential co-primary measures for psychometric properties and validity... - Routine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERIAlexander S Young
VA Desert Pacific Mental Illness Research, Education and Clinical Center MIRECC, West Los Angeles VA, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA
Community Ment Health J 47:123-35. 2011..There are validated instruments and assessment strategies that are feasible for quality improvement in routine practice... - Psychosocial treatments to promote functional recovery in schizophreniaRobert S Kern
Veterans Affairs Greater Los Angeles Healthcare System MIRECC 210 A, Building 210, Room 116, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA
Schizophr Bull 35:347-61. 2009..Overall, these treatments provide a range of promising approaches to helping patients achieve better outcomes far beyond symptom stabilization... - Determination of ziprasidone in human plasma by liquid chromatography-electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patientsManickam Aravagiri
Veterans Administration Greater Los Angeles Healthcare System, UCLA, Los Angeles, CA, USA
J Chromatogr B Analyt Technol Biomed Life Sci 847:237-44. 2007..The data showed large inter-individual variations... - Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illnessStephen R Marder
Department of Psychiatry and Biobehavioral Sciences, Mental Illness Research, Education, and Clinical Center (MIRECC, West Los Angeles VA Healthcare Center, Los Angeles, CA, USA
J Clin Psychiatry 67:e03. 2006..By focusing on cognitive impairments and negative symptoms, the functional outcomes of patients with schizophrenia may be improved... - Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophreniaJin Hun Kim
Schizophrenia Research Group, Department of Psychiatry, Seoul National Hospital, Seoul, Republic of Korea
Prog Neuropsychopharmacol Biol Psychiatry 32:984-8. 2008..These findings suggest that clozapine should be considered for the treatment of schizophrenia patients with comorbid AUD. However, due to the limitations of this study, further studies will be required to confirm these findings... - The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validityKeith H Nuechterlein
Department of Psychology, UCLA Semel Institute for Neuroscience and Human Behavior, 300 Medical Plaza, Rm 2251, Los Angeles, CA 90095 6968, USA
Am J Psychiatry 165:203-13. 2008.... - The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardizationRobert S Kern
Department of Psychology, Geffen School of Medicine, University of California, Los Angeles CA 90073, USA
Am J Psychiatry 165:214-20. 2008..S. community sample with the battery administered as a unit... - A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophreniaJoseph M Pierre
Department of Psychiatry, Veterans Administration Greater Los Angeles Healthcare System, and David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, USA
J Clin Psychiatry 68:705-10. 2007.... - Chronic restlessness with antipsychoticsIrene M Bratti
San Diego VA Mental Illness Research, Education, and Clinical Center, CA, USA
Am J Psychiatry 164:1648-54. 2007 - Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trialJonathan K Wynn
Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA
Schizophr Res 95:134-42. 2007..The results are discussed in terms of animal models, neural substrates, and treatment implications... - Treatment of schizophrenia negative symptoms: future prospectsStephen M Erhart
UCLA Department of Psychiatry and Biobehavioral Sciences, USA
Schizophr Bull 32:234-7. 2006..We review the continuing limitations in treatment and discuss possible sources of heterogeneity among negative symptoms. We also anticipate conceptual uncertainties that may arise with forthcoming treatment developments... - The effects of novel antipsychotics on glucose and lipid levelsDonna A Wirshing
Department of Psychiatry, VA Greater Los Angeles Healthcare System, and University of California at Los Angeles, School of Medicine, 90073, USA
J Clin Psychiatry 63:856-65. 2002..The goal of this study is to compare the effects of novel antipsychotics clozapine, olanzapine, risperidone, and quetiapine and typical antipsychotics haloperidol and fluphenazine on glucose and lipid levels... - Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophreniaShirley M Glynn
Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles and Veteran Affairs Greater Los Angeles Healthcare System, 90073, USA
Am J Psychiatry 159:829-37. 2002.... - Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to ratsManickam Aravagiri
Psychopharmacology Unit, University of California at Los Angeles, VA Greater Los Angeles Healthcare System, Building 210, 15, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA
Psychopharmacology (Berl) 159:424-31. 2002.... - Sexual side effects of novel antipsychotic medicationsDonna A Wirshing
Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine and VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA
Schizophr Res 56:25-30. 2002..The novel antipsychotic medications offer a more favorable extrapyramidal side effect profile than conventional agents. It is uncertain that the novel antipsychotics have a benefit in terms of sexual side effects... - Anterior cingulate dysfunction during choice anticipation in schizophreniaJavier Quintana
Greater Los Angeles VA Health Care System and VA VISN22 Mental Illness, Research, Education and Clinical Center, Los Angeles, CA 90073, USA
Psychiatry Res 132:117-30. 2004..These results reveal an ACGC dysfunction during choice anticipation in schizophrenia and suggest that it might underlie the foresight deficits seen in schizophrenic patients... - Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidoneManickam Aravagiri
Psychopharmacology Unit, University of California at Los Angeles, VA Greater Los Angeles Healthcare System, Bldg 210 15, 11301 Wilshire Blvd, Los Angeles, California, USA
Ther Drug Monit 25:657-64. 2003..The current data support the fact that it is important to measure steady-state levels of total active moiety by analyzing both RSP and 9-OHRSP for plasma drug monitoring... - In vivo amplified skills training: promoting generalization of independent living skills for clients with schizophreniaRobert P Liberman
UCLA Department of Psychiatry and Biobehavioral Sciences, UCLA Psych REHAB Program, 300 UCLA Medical Plaza, Ste 2263, Los Angeles, CA 90095
Psychiatry 65:137-55. 2002..Obstacles to success of IVAST may derive from deficits in personal motivation, family involvement, community support, financial resources, premorbid functioning, and medication compliance... - Clinical utility of magnetic resonance imaging radiographs for suspected organic syndromes in adult psychiatryStephen M Erhart
Department of Veterans Affairs Health Care Center Greater Los Angeles, Los Angeles, CA, USA
J Clin Psychiatry 66:968-73. 2005..We identified the most common signs and symptoms prompting MRIs to establish the predictive value of these signs and symptoms for clinically pertinent organic syndromes... - Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteriaMichael F Green
Neuropsychiatric Institute, Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
Biol Psychiatry 56:301-7. 2004..The results from this meeting constitute the initial steps for reaching a consensus cognitive battery for clinical trials in schizophrenia... - Evidence-based pharmacologic treatment for people with severe mental illness: a focus on guidelines and algorithmsT A Mellman
Department of Psychiatry, Dartmouth Medical School, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA
Psychiatr Serv 52:619-25. 2001.... - Better pharmacotherapy for schizophrenia: what does the future hold?Michael A Webber
Semel Institute for Neuroscience at UCLA, Mental Illness Research, Education, and Clinical Center, VA West Los Angeles Health Care Center, MIRECC 210A, 11301 Wilshire Boulevard, Los Angeles, CA 90073 1003, USA
Curr Psychiatry Rep 10:352-8. 2008..The goal of this future pharmacotherapy strategy is to advance outcomes beyond psychosis remission and toward functional recovery... - A review of agitation in mental illness: treatment guidelines and current therapiesStephen R Marder
Department of Psychiatry, David Geffen School of Medicine at the University of California Los Angeles, VISN 22 Mental Illness Research, Education, and Clinical Center, Los Angeles, Calif, USA
J Clin Psychiatry 67:13-21. 2006..Agitation is an important therapeutic target in the acute and/or emergent setting, as well as for longer-term care of patients with psychiatric illness... - MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjectsG Bartzokis
North Little Rock VA Medical Center, Department of Psychiatry, University of Arkansas for Medical Sciences, 72114, USA
Magn Reson Imaging 17:213-22. 1999..The FDRI results suggest that disregulation of iron metabolism occurs in PD and that this disregulation may differ in earlier- versus later-onset PD... - Right lateral fusiform gyrus dysfunction during facial information processing in schizophreniaJavier Quintana
West Los Angeles VA Health Care Center, and Department of Psychiatry, School of Medicine, University of California at Los Angeles, Los Angeles, California 90024-1759, USA
Biol Psychiatry 53:1099-112. 2003..CONCLUSIONS: These results indicate a specific rLFG dysfunction during early facial information--identity or affect--processing, independent from other cognitive deficits, in schizophrenia... - A compensatory mirror cortical mechanism for facial affect processing in schizophreniaJ Quintana
West Los Angeles VA HCC, School of Medicine, University of California at Los Angeles, Los Angeles, CA 90024, USA
Neuropsychopharmacology 25:915-24. 2001..We found that, when the task cues were facial expressions in contrast to color circles, the schizophrenic group exhibited increased activation of the face movement areas in motor and pre-motor cortex... - Methodological issues in negative symptom trialsStephen R Marder
The Semel Institute for Neuroscience at University of California, Los Angeles, CA
Schizophr Bull 37:250-4. 2011.... - Bipolar I disorder: psychopathology, medical management and dental implicationsArthur H Friedlander
West Valley Los Angeles County Department of Health, Van Nuys, Calif, USA
J Am Dent Assoc 133:1209-17. 2002..The authors review the clinical features, epidemiology, pathophysiology, medical management, dental findings and dental management of patients who have bipolar I disorder, or BD, previously known as manic-depressive disorder... - Sex, race, and smoking impact olanzapine exposureKristin L Bigos
Department of Pharmaceutical Sciences, University of Pittsburgh, School of Pharmacy, 805 Salk Hall, 3501 Terrace St, Pittsburgh, PA 15261, USA
J Clin Pharmacol 48:157-65. 2008..0001). Differences in olanzapine exposure due to sex, race, and smoking may account for some of the variability in response to olanzapine... - Clinical predictors of response to clozapine treatment in ambulatory patients with schizophreniaDaniel S Umbricht
Department of Psychiatric Research, Psychiatric University Hospital, Zurich, Switzerland
J Clin Psychiatry 63:420-4. 2002..Clinicians would be well served if clinical characteristics could be identified that predict a favorable response to clozapine. A few studies addressing this issue have reported inconsistent results... - Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophreniaBaojin Zhu
Eli Lilly and Company, Lilly Corporate Center Drop 4133, Indianapolis, IN 46285, USA
Psychiatr Serv 59:315-7. 2008..This study compared the time to discontinuation for any reason of first-generation antipsychotics--in oral versus depot formulation--in the usual care of schizophrenia... - The NIMH-MATRICS consensus statement on negative symptomsBrian Kirkpatrick
Department of Psychiatry and Health Behavior, Medical College of Georgia, USA
Schizophr Bull 32:214-9. 2006 - Newer antipsychotics and the differences between clinical experiences and clinical trials. Interview by Norman Sussman, MDStephen R Marder
CNS Spectr 12:812-5. 2007 - Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorderIra D Glick
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 101 Quarry Road 2122, Stanford, CA 94305, USA
J Clin Psychiatry 66:638-41. 2005..To compare the long-term efficacy and tolerability of oral quetiapine with those of intramuscular haloperidol... - Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategyLawrence J Albers
VA Long Beach Healthcare System, Department of Psychiatry and Human Behavior, College of Medicine, University of California Irvine, CA 90822, USA
J Clin Psychopharmacol 25:170-4. 2005..05). In conclusion, this prospective pilot study suggests that a 26% reduction in olanzapine therapeutic dose requirement may be achieved by coadministration of a nontherapeutic oral dose of fluvoxamine... - The heterogeneity of schizophrenia in disease statesPenny E Mohr
Centers for Medicare and Medicaid Services, ORDI REG DBR, Mail stop C3 19 07 7500, Security Boulevard, Baltimore, MD 21244, USA
Schizophr Res 71:83-95. 2004.... - Social cognition in schizophrenia: relationships with neurocognition and negative symptomsMark J Sergi
Department of Psychology, California State University at Northridge, Northridge, CA 91330 8255, USA
Schizophr Res 90:316-24. 2007..The current findings start to provide insights into the structure of social cognition, neurocognition, and negative symptoms in schizophrenia... - Switch or stay?John M Davis
Am J Psychiatry 163:2032-3. 2006 - Lessons from each drug trialStephen R Marder
Am J Psychiatry 164:375-6. 2007 - Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophreniaLizheng Shi
Department of Health Systems Management, School of Public Health and Tropical Medicine, Tulane University, 1440 Canal St, Suite 1900, New Orleans, LA 70112, USA
Psychiatr Serv 58:482-8. 2007.... - Do clozapine and risperidone affect social competence and problem solving?Alan S Bellack
Mental Health Research, Education and Clinical Center, VA Maryland Health Care System, Baltimore 21201, USA
Am J Psychiatry 161:364-7. 2004..The purpose of this investigation was to evaluate the effects of clozapine and risperidone on social skill and problem solving in patients with schizophrenia... - Schizophrenia, IX: Cognition in schizophrenia--the MATRICS initiativeStephen R Marder
Am J Psychiatry 161:25. 2004 - Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidolMark J Sergi
Department of Psychology, California State University, 18111 Nordhoff St, Northridge, CA 91330 8255, USA
Am J Psychiatry 164:1585-92. 2007..This study examined the short-term effects of first- and second-generation antipsychotic medications on social cognition and basic cognition... - The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairmentsRobert W Buchanan
Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
Am J Psychiatry 164:1593-602. 2007..Agents that act at the glycine site of the N-methyl-D-aspartic acid (NMDA) glutamatergic receptor have been suggested as promising treatments for moderate to severe negative symptoms and cognitive impairments... - Olanzapine treatment for patients with schizophrenia and cocaine abuseJohn Tsuang
J Clin Psychiatry 63:1180 -1. 2002 - Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioningMarco C G Merlo
Hĵpitaux Universitaires de Genève, Departement de Psychiatrie, Chene Bourg, Switzerland
J Clin Psychiatry 63:885-91. 2002..The aim of this study was to examine differences in the improvement of clinical psychopathology and in fine motor functions at 2 doses of risperidone in first-episode, acutely psychotic patients... - New paradigms for treatment developmentEllen L Stover
National Institute of Mental Health, Bethesda, MD, USA
Schizophr Bull 33:1093-9. 2007....
Research Grants
- TREATMENT OF NEGATIVE SYMPTOMS & COGNITIVE IMPAIRMENTSStephen Marder; Fiscal Year: 2003..The study will provide new information on the efficacy of d- cycloserine and glycine for both persistent primary and secondary negative symptoms and its effect on cognitive functioning. ..
- MANAGEMENT OF RISK FOR RELAPSE IN SCHIZOPHRENIAStephen Marder; Fiscal Year: 1990
- MANAGEMENT FOR RISK OF RELAPSE IN SCHIZOPHRENIAStephen Marder; Fiscal Year: 1993....
- MANAGEMENT FOR RISK OF RELAPSE IN SCHIZOPHRENIAStephen Marder; Fiscal Year: 2004..The investigator will evaluate outcome during the next two years with measures of clinical psychopathology, medication side effects, functional outcomes, and quality of life. ..